- IP hearings this week
- IP trials
- IP Judicial review hearings
- IP appeals at the Federal Court of Appeal
(As published on the Federal Court and Federal Court of Appeal websites on May 12, 2025)
This week in IP
| Date | File No. | Type | Name | Location | Length |
| May 13, 2025 | A-125-24 | APP | ComitÉ Interprofessionnel Du Vin De Champagne Et Al C. Coors Brewing Company (Trade-mark) | Toronto | 0 |
| May 13, 2025 | T-2423-24 | CMC | The Construction Specifications Institu V. Bibliotech Inc. Et Al. (Copyright) | Ottawa | 1 h |
| May 14, 2025 | T-2137-23 | M | Bayer Inc. Et Al. V. Amgen Canada Inc. (Patent) | Toronto | 3 h |
| May 15, 2025 | T-91-20 | MED | University Of Saskatchewan Et Al. V. Newagco Inc. Et Al. (Patent) | Montréal | 1 d |
| May 15, 2025 | T-1917-23 | M | Bayer Inc And Regeneron Pharmaceuticals, Inc V. Amgen Canada Inc (Patent) | Ottawa | 3 h |
| May 15, 2025 | T-1918-23 | M | Bayer Inc Et Al., V. Amgen Canada Inc (Patent) | Ottawa | 3 h |
| May 15, 2025 | T-1245-25 | CMC | Boehringer Ingelheim (canada) Ltd. Et Al. V. Auro Pharma Inc. (Patent - Empagliflozin*) | Ottawa | 1 h |
| May 16, 2025 | T-2137-23 | M | Bayer Inc. Et Al. V. Amgen Canada Inc. (Patent) | Toronto | 3 h |
Return to top.
Scheduled IP Trials
| Date | File No. | Name | Location | Length |
| Apr 28, 2025 | T-1288-18 | Gemak Trust V. Jempak Corporation Et Al (Patent) | Toronto | 15 d |
| Apr 28, 2025 | T-1184-21 | Adeia Guides, Inc. Et Al. V. Bce Inc. Et Al. (Patent) | Toronto | 21 d |
| May 21, 2025 | T-1288-18 | Gemak Trust V. Jempak Corporation Et Al (Patent) | Toronto | 3 d |
| May 26, 2025 | T-732-22 | Pharmascience Inc. V. Janssen Inc. Et Al. (PMNOC - Section 8 - Abiraterone*) | Toronto | 10 d |
| May 26, 2025 | T-2137-23 | Bayer Inc. Et Al. V. Amgen Canada Inc. (Patent) | Toronto | 10 d |
| Jun 2, 2025 | T-1184-21 | Adeia Guides, Inc. Et Al. V. Bce Inc. Et Al. (Patent) | Toronto | 3 d |
| Jun 11, 2025 | T-2137-23 | Bayer Inc. Et Al. V. Amgen Canada Inc. (Patent) | Toronto | 2 d |
| Jun 12, 2025 | T-732-22 | Pharmascience Inc. V. Janssen Inc. Et Al. (PMNOC - Section 8 - Abiraterone*) | Toronto | 1 d |
| Jul 2, 2025 | T-2011-23 | Alexion Pharmaceuticals Inc. Et Al. V Samsung Bioepis Co., Ltd (Patent) | Toronto | 7 d |
| Jul 16, 2025 | T-2011-23 | Alexion Pharmaceuticals Inc. Et Al. V Samsung Bioepis Co., Ltd (Patent) | Toronto | 2 d |
| Aug 12, 2025 | T-954-18 | Deeproot Green Infrastructure, Llc Et Al V. Greenblue Urban North America In (Patent) | Ottawa | 1 d |
| Aug 18, 2025 | T-1917-23 | Bayer Inc And Regeneron Pharmaceuticals, Inc V. Amgen Canada Inc (Patent) | Toronto | 10 d |
| Aug 18, 2025 | T-1918-23 | Bayer Inc Et Al., V. Amgen Canada Inc (Patent) | Toronto | 10 d |
| Sep 2, 2025 | T-1917-23 | Bayer Inc And Regeneron Pharmaceuticals, Inc V. Amgen Canada Inc (Patent) | Toronto | 2 d |
| Sep 2, 2025 | T-1918-23 | Bayer Inc Et Al., V. Amgen Canada Inc (Patent) | Toronto | 2 d |
| Sep 8, 2025 | T-351-24 | Aralez Pharmaceuticals Canada Inc. V. Taro Pharmaceuticals Inc. Et Al. (Patent) | To be determined (TrialJA) | 5 d |
| Sep 19, 2025 | T-351-24 | Aralez Pharmaceuticals Canada Inc. V. Taro Pharmaceuticals Inc. Et Al. (Patent) | To be determined (TrialJA) | 1 d |
| Oct 20, 2025 | T-886-21 | The Toronto-dominion Bank V. Thomas John Dyas Et Al (Trademark) | Toronto | 5 d |
| Oct 27, 2025 | T-156-24 | Viiv Healthcare Company Et Al. V. Pharmascience Inc. (Patent) | Toronto | 10 d |
| Nov 12, 2025 | T-156-24 | Viiv Healthcare Company Et Al. V. Pharmascience Inc. (Patent) | Toronto | 2 d |
| Nov 12, 2025 | T-1779-23 | Samsung Bioepis Co., Ltd V. Alexion Pharmaceuticals, Inc. (Copyright) | Toronto | 28 d |
| Nov 12, 2025 | T-1584-23 | Amgen Canada Inc. V. Alexion Pharmaceuticals, Inc. (Patent) | Toronto | 28 d |
| Nov 17, 2025 | T-1425-20 | Energy Intelligence Group, Inc. Et Al. V. Rbc Dominion Securities Inc. Et Al (Copyright) | Toronto | 5 d |
| Nov 24, 2025 | T-91-20 | University Of Saskatchewan Et Al. V. Newagco Inc. Et Al. (Patent) | Toronto | 8 d |
| Nov 24, 2025 | T-938-24 | Viiv Healthcare Company Et Al V. Jamp Pharma Corporation (Patent) | Toronto | 12 d |
| Dec 1, 2025 | T-675-24 | Pfizer Canada Ulc Et Al. V. Glenmark Pharmaceuticals Canada Inc. Et Al. (Patent) | To be determined (TrialJA) | 10 d |
| Dec 1, 2025 | T-1188-23 | 7299362 Canada Inc. C.o.b. As Alexa Translations V. Amazon.com, Inc. Et Al. (Trade Mark) | Toronto | 15 d |
| Dec 8, 2025 | T-91-20 | University Of Saskatchewan Et Al. V. Newagco Inc. Et Al. (Patent) | Toronto | 2 d |
| Dec 8, 2025 | T-923-24 | Janssen Inc. And Mitsubishi Tanabe Pharma Corporation V. Apotex Inc. (Patent) | Toronto | 8 d |
| Dec 15, 2025 | T-938-24 | Viiv Healthcare Company Et Al V. Jamp Pharma Corporation (Patent) | Toronto | 3 d |
| Jan 7, 2026 | T-745-24 | Viiv Healthcare Company Et Al V. Sandoz Canada Inc. (Patent) | Toronto | 8 d |
| Jan 19, 2026 | T-2405-23 | Bailey Metal Products Limited V. Dcm Metal Corp. (Patent) | Toronto | 5 d |
| Jan 22, 2026 | T-745-24 | Viiv Healthcare Company Et Al V. Sandoz Canada Inc. (Patent) | Toronto | 2 d |
| Jan 28, 2026 | T-2405-23 | Bailey Metal Products Limited V. Dcm Metal Corp. (Patent) | Toronto | 1 d |
| Feb 2, 2026 | T-400-22 | Pharmascience Inc. V. Biogen Canada Inc. Et Al. (PMNOC - Section 8 - Fampridine*) | Ottawa | 15 d |
| Mar 2, 2026 | T-1583-24 | Novartis Pharmaceuticals Canada Inc. V. Apotex Inc. Et Al. (Patent - Ruxolitinib*) | To be determined (TrialJA) | 8 d |
| Mar 2, 2026 | T-1584-24 | Novartis Pharmaceuticals Canada Inc. V. Apotex Inc. Et Al. (Patent - Ruxolitinib*) | To be determined (TrialJA) | 8 d |
| Mar 9, 2026 | T-1346-21 | Federation Of Asian Canadians Toronto V. Asialicious Holdings Inc. Et Al. (Trade Mark) | Toronto | 5 d |
| Mar 16, 2026 | T-2324-23 | Samsung Bioepis Co., Ltd. V Janssen Biotech, Inc. (Patent) | Toronto | 9 d |
| Mar 16, 2026 | T-1321-24 | Lundbeck Canada Inc. Et Al. V. Jamp Pharma Corporation (Patent - Vortioxetine*) | To be determined (TrialJA) | 8 d |
| Mar 16, 2026 | T-1583-24 | Novartis Pharmaceuticals Canada Inc. V. Apotex Inc. Et Al. (Patent - Ruxolitinib*) | To be determined (TrialJA) | 2 d |
| Mar 16, 2026 | T-1584-24 | Novartis Pharmaceuticals Canada Inc. V. Apotex Inc. Et Al. (Patent - Ruxolitinib*) | To be determined (TrialJA) | 2 d |
| Mar 23, 2026 | T-1662-24 | Eisai Limited And Eisai R&d Et Al. V. Dr. Reddy's Laboratories Ltd. (Patent - Lenvatinib*) | Toronto | 8 d |
| Mar 30, 2026 | T-1321-24 | Lundbeck Canada Inc. Et Al. V. Jamp Pharma Corporation (Patent - Vortioxetine*) | To be determined (TrialJA) | 2 d |
| Apr 7, 2026 | T-2324-23 | Samsung Bioepis Co., Ltd. V Janssen Biotech, Inc. (Patent) | Toronto | 1 d |
| Apr 7, 2026 | T-1608-24 | Aralez Pharmaceuticals Canada Inc. V. Jamp Pharma Corporation And Al (Patent - Diclofenac*) | To be determined (TrialJA) | 16 d |
| Apr 7, 2026 | T-1387-24 | Aralez Pharmaceuticals Canada Inc. V. Jamp Pharma Corporation Et Al. (Patent - Diclofenac*) | To be determined (TrialJA) | 16 d |
| Apr 15, 2026 | T-1662-24 | Eisai Limited And Eisai R&d Et Al. V. Dr. Reddy's Laboratories Ltd. (Patent - Lenvatinib*) | Toronto | 2 d |
| May 11, 2026 | T-2102-24 | Nuvo Pharmaceuticals V. Auro Pharma Inc. Et Al. (Patent - Naproxen*) | Toronto | 9 d |
| May 25, 2026 | T-2593-24 | Janssen Inc. Et Al. V. Pharmascience Inc. (Patent - Macitentan*) | Toronto | 4 d |
| May 28, 2026 | T-2102-24 | Nuvo Pharmaceuticals V. Auro Pharma Inc. Et Al. (Patent - Naproxen*) | Toronto | 2 d |
| Jun 1, 2026 | T-2593-24 | Janssen Inc. Et Al. V. Pharmascience Inc. (Patent - Macitentan*) | Toronto | 2 d |
| Jun 8, 2026 | T-2593-24 | Janssen Inc. Et Al. V. Pharmascience Inc. (Patent - Macitentan*) | Toronto | 2 d |
| Jun 15, 2026 | T-3154-24 | Emd Serono Et Al. V. Auro Pharma Inc. (Patent - Cladribine*) | Toronto | 10 d |
| Jun 15, 2026 | T-2962-24 | Pfizer Canada Ulc Et Al. V. Taro Pharmaceuticals Inc. (Patent - Bosutinib*) | Toronto | 10 d |
| Jun 30, 2026 | T-3154-24 | Emd Serono Et Al. V. Auro Pharma Inc. (Patent - Cladribine*) | Toronto | 1 d |
| Aug 10, 2026 | T-3401-24 | Takeda Pharmaceuticals U.s.a., Inc Et Al. V. Apotex Inc. (Patent - Ponatinib*) | To be determined (TrialJA) | 5 d |
| Aug 17, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 17, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 17, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 20, 2026 | T-3401-24 | Takeda Pharmaceuticals U.s.a., Inc Et Al. V. Apotex Inc. (Patent - Ponatinib*) | To be determined (TrialJA) | 2 d |
| Aug 24, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 24, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 24, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 31, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 31, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Aug 31, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 4 d |
| Sep 8, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 3 d |
| Sep 8, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 3 d |
| Sep 8, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 3 d |
| Oct 19, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 4 d |
| Oct 19, 2026 | T-243-25 | Bayer Inc. Et Al V. Sandoz Canada Inc. (Patent - Aflibercept*) | Toronto | 4 d |
| Oct 19, 2026 | T-1059-22 | Seylynn (north Shore) Development Limited Partnership V. Denna Homes Group (Trade Mark) | Vancouver | 10 d |
| Oct 26, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 4 d |
| Oct 26, 2026 | T-376-25 | Emergent Operations Ireland Limited Et Al. V. Padagis Israel Pharmaceuitcal (Patent - Naloxone*) | Toronto | 9 d |
| Oct 26, 2026 | T-243-25 | Bayer Inc. Et Al V. Sandoz Canada Inc. (Patent - Aflibercept*) | Toronto | 4 d |
| Nov 2, 2026 | T-243-25 | Bayer Inc. Et Al V. Sandoz Canada Inc. (Patent - Aflibercept*) | Toronto | 4 d |
| Nov 4, 2026 | T-1059-22 | Seylynn (north Shore) Development Limited Partnership V. Denna Homes Group (Trade Mark) | Vancouver | 2 d |
| Nov 9, 2026 | T-376-25 | Emergent Operations Ireland Limited Et Al. V. Padagis Israel Pharmaceuitcal (Patent - Naloxone*) | Toronto | 1 d |
| Nov 9, 2026 | T-243-25 | Bayer Inc. Et Al V. Sandoz Canada Inc. (Patent - Aflibercept*) | Toronto | 4 d |
| Nov 18, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 2 d |
| Nov 23, 2026 | T-742-25 | Salix Pharmaceuticals, Inc. V. Sandoz Canada Inc. (Patent) | Toronto | 8 d |
| Nov 23, 2026 | T-887-25 | Boehringer Ingelheim (canada) Ltd Et Al V. Auro Pharma Inc (Patent - Empagliflozin*) | To be determined (TrialJA) | 13 d |
| Dec 7, 2026 | T-742-25 | Salix Pharmaceuticals, Inc. V. Sandoz Canada Inc. (Patent) | Toronto | 2 d |
| Dec 17, 2026 | T-887-25 | Boehringer Ingelheim (canada) Ltd Et Al V. Auro Pharma Inc (Patent - Empagliflozin*) | To be determined (TrialJA) | 2 d |
Return to top.
Scheduled Judicial Review Hearings
| Date | File No. | Name | Type | Location | Length |
| Jun 10, 2025 | T-1990-24 | 2718971 Ontario Inc V. Kinde Company Ltd. | Trade Mark - Appeal of a decision of the Registrar | Toronto | 1 d |
Return to top.
Scheduled IP Appeals
| Date | File No. | Name | Type | Location |
| May 13, 2025 | A-125-24 | ComitÉ Interprofessionnel Du Vin De Champagne Et Al C. Coors Brewing Company | Appeal (S.27 - Final) - Trade-marks Act | Toronto |
* Medicinal ingredients are based on automated analysis and should not be relied upon.
Return to top.